<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03238989</url>
  </required_header>
  <id_info>
    <org_study_id>ILD Registry</org_study_id>
    <nct_id>NCT03238989</nct_id>
  </id_info>
  <brief_title>Interstitial Lung Disease Registry Construction</brief_title>
  <acronym>ILD Registry</acronym>
  <official_title>Interstitial Lung Disease Registry Construction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is investigating the clinical course, treatment course, and&#xD;
      prognosis of patients with interstitial lung disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial lung disease refers to pulmonary disease that occurs in the interstitium of the&#xD;
      lung.&#xD;
&#xD;
      It can be broadly classified into lung disease secondary to the cause of systemic disease or&#xD;
      drug, and lung disease whose cause is unknown, and the latter is known as idiopathic&#xD;
      interstitial pneumonia.&#xD;
&#xD;
      Idiopathic interstitial pneumonia is a lung disease showing various aspects of inflammatory&#xD;
      response and fibrosis reaction, and the cause of the onset is not accurately known yet, also&#xD;
      there is no effective treatment.&#xD;
&#xD;
      Idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis, progresses very&#xD;
      slowly, but sometimes acute exacerbation without any obvious cause leads to death, rapidly.&#xD;
&#xD;
      Therefore, it is important to collect data prospectively for changes in clinical features,&#xD;
      pulmonary function, imaging findings, and quality of life of these patients.&#xD;
&#xD;
      A prospective study of idiopathic interstitial pneumonia will provide important information&#xD;
      on the clinical characteristics and admission history of patients with idiopathic&#xD;
      interstitial pneumonia, and the idiopathic interstitial pneumonia registry system will serve&#xD;
      as the basis for further prospective observational studies.&#xD;
&#xD;
      The aim of this study is to establish the registry of patients with interstitial lung disease&#xD;
      and to prospectively review the clinical features and progression of the patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>St George's Respiratory Questionnaire(SGRQ)</measure>
    <time_frame>at baseline, every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in clinical symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modified Medical Research Council (mMRC) dyspnea scale</measure>
    <time_frame>at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in clinical symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Borg dyspnea scale</measure>
    <time_frame>at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in clinical symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospital anxiety and depression score(HADS)</measure>
    <time_frame>at baseline, every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in clinical symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>chest X-ray</measure>
    <time_frame>at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in chest radiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chest CT</measure>
    <time_frame>at baseline, every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in chest radiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Paranasal sinus X-ray(PNS series)</measure>
    <time_frame>at baseline</time_frame>
    <description>baseline PNS X-ray</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram(ECG)</measure>
    <time_frame>at baseline</time_frame>
    <description>baseline ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulmonary function test with bronchodilator response test(PFT+BDR)</measure>
    <time_frame>at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in lung function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusing capacity of the lungs for carbon monoxide(DLCO)</measure>
    <time_frame>at baseline, after 1 month, after 3 month, and then every 1 year through study completion for 10 years</time_frame>
    <description>monitoring changes in lung function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>total lung capacity(TLC)</measure>
    <time_frame>at baseline</time_frame>
    <description>monitoring changes in lung function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bronchoscopic alveolar lavage(BAL)</measure>
    <time_frame>at baseline</time_frame>
    <description>for diagnostic purposes if necessary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Video-assisted thoracoscopic surgery(VATS) lung biopsy</measure>
    <time_frame>at baseline</time_frame>
    <description>for diagnostic purposes if necessary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>echocardiography</measure>
    <time_frame>at baseline</time_frame>
    <description>additionally tested at acute exacerbation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>arterial blood gas analysis(ABGA)</measure>
    <time_frame>at baseline</time_frame>
    <description>additionally tested at acute exacerbation</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>monitoring changes in clinical symptoms, pulmonary function, and chest radiography</intervention_name>
    <description>For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient, ward&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 20 years diagnosed with interstitial lung disease&#xD;
&#xD;
          -  Diagnostic criteria for interstitial lung disease. If one of the following is met:&#xD;
&#xD;
               1. clinical suspicion of idiopathic pulmonary fibrosis (IPF); Characteristic chest&#xD;
                  CT findings with honeycomb cysts and fibrosis and reasonable clinical signs&#xD;
&#xD;
               2. suspected interstitial pneumonia, or confirmed by biopsy with no evidence of&#xD;
                  infection : IPF, Non-specific interstitial pneumonia(NSIP), Cryptogenic&#xD;
                  organizing pneumonia(COP), unclassified fibrosis&#xD;
&#xD;
               3. interstitial lung disease suspects with underlying rheumatic disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No specific criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Choi Sun Mi</last_name>
    <phone>02-2072-4915</phone>
    <email>sunmich81@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PARK HEEMOON</last_name>
    <email>coramdeo33@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choi Sun Mi</last_name>
      <phone>02-2072-4915</phone>
      <email>sunmich81@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>PARK HEEMOON</last_name>
      <email>coramdeo33@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2017</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Sun Mi Choi</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Interstitial lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

